GALECTIN THERAPEUTICS INC — Director's Dealing 2018

Jun 20, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2018-06-14

Reporting Person: CZIRR JAMES C (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-14	Common Stock	S	31860	$7.99	Disposed	2769786	Indirect
2018-06-14	Common Stock	S	44525	$8.48	Disposed	2725261	Indirect
2018-06-15	Common Stock	S	15475	$8.47	Disposed	2709786	Indirect
2018-06-18	Common Stock	S	60000	$9.06	Disposed	2649786	Indirect

Footnotes

F1: Common shares should pursuant to a trading plan pursuant to Rule 10b5-1. Price represents the gross sales price less commissions and brokerage fees.

F2: The transaction was consummated by 10X Fund, L.P., a Delaware limited partnership, and not by the Reporting Person. The Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his after fund payout pecuniary interest therein.